- Home
- SCNI vs LIXT Comparison
SCNI vs LIXT Comparison
Compare SCNI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- LIXT
- Stock Information
- Founded
- SCNI 2003
- LIXT 2005
- Country
- SCNI Israel
- LIXT United States
- Employees
- SCNI N/A
- LIXT N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- LIXT Health Care
- Exchange
- SCNI Nasdaq
- LIXT Nasdaq
- Market Cap
- SCNI 3.5M
- LIXT 4.1M
- IPO Year
- SCNI N/A
- LIXT N/A
- Fundamental
- Price
- SCNI $3.39
- LIXT $1.91
- Analyst Decision
- SCNI
- LIXT
- Analyst Count
- SCNI 0
- LIXT 0
- Target Price
- SCNI N/A
- LIXT N/A
- AVG Volume (30 Days)
- SCNI 13.0K
- LIXT 33.2K
- Earning Date
- SCNI 11-22-2024
- LIXT 11-12-2024
- Dividend Yield
- SCNI N/A
- LIXT N/A
- EPS Growth
- SCNI N/A
- LIXT N/A
- EPS
- SCNI 8.20
- LIXT N/A
- Revenue
- SCNI $452,000.00
- LIXT N/A
- Revenue This Year
- SCNI N/A
- LIXT N/A
- Revenue Next Year
- SCNI N/A
- LIXT N/A
- P/E Ratio
- SCNI $0.42
- LIXT N/A
- Revenue Growth
- SCNI N/A
- LIXT N/A
- 52 Week Low
- SCNI $2.23
- LIXT $1.31
- 52 Week High
- SCNI $8.92
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- SCNI 51.16
- LIXT 49.00
- Support Level
- SCNI $3.20
- LIXT $1.85
- Resistance Level
- SCNI $3.55
- LIXT $2.65
- Average True Range (ATR)
- SCNI 0.19
- LIXT 0.20
- MACD
- SCNI 0.02
- LIXT 0.01
- Stochastic Oscillator
- SCNI 47.50
- LIXT 12.94
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.